 | NEW VISTAS IN THERAPEUTICS: FROM DRUG DESIGN TO GENE THERAPY
Copyright © 2001 by the New York Academy of Sciences
description
Annals of the New York Academy of Sciences 953:53-63 (2001)
© 2001 New York Academy of Sciences
Regulated Gene Expression in Gene Therapy
PHILIP W. ZOLTICKa,b AND
JAMES M. WILSONa,b,c
aInstitute for Human Gene Therapy, bDepartment of Molecular and Cellular Engineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
cThe Wistar Institute, Philadelphia, Pennsylvania 19104, USA
Address for correspondence: James M. Wilson, M.D., Ph.D., 204 Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104-4268. Voice: 215-898-3000; fax: 215-898-6588.
wilsonjm{at}mail.med.upenn.edu
The original model of gene therapy, that of efficient delivery, durable transfer, and stable expression of transgenes to correct a gene defect underlying an inherited disease, is limited in light of improved understanding of the processes involved. Techniques that enable regulated expression of transgenes may enhance safety and allow us to regulate the timing and level of expression with a goal of precisely targeting a therapeutic level between the extremes of suboptimal and supraoptimal thresholds. Using regulated systems to control protein expression has practical and possibly essential roles for the success of safe and effective gene therapy in a number of clinical situations. Pharmacologically regulated gene expression is an evolving tool, and no individual system may be effective in all clinical applications.
Key Words: gene therapy • transgene • regulated gene expression • genetic diseases • ligand-based gene expression
This article has been cited by other articles:
|
|
|
|
 
A. Blesch and M. H. Tuszynski
Transient Growth Factor Delivery Sustains Regenerated Axons after Spinal Cord Injury
J. Neurosci.,
September 26, 2007;
27(39):
10535 - 10545.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. H. Evans, S. C. Ghivizzani, J. H. Herndon, and P. D. Robbins
Gene Therapy for the Treatment of Musculoskeletal Diseases
J. Am. Acad. Ortho. Surg.,
July 1, 2005;
13(4):
230 - 242.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Fukazawa, Y. Maeda, F. M. Sladek, and L. B. Owen-Schaub
Development of a Cancer-Targeted Tissue-Specific Promoter System
Cancer Res.,
January 1, 2004;
64(1):
363 - 369.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
